Findings of Research Misconduct, 40157 [E7-14185]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 140 / Monday, July 23, 2007 / Notices
funds, positions, personnel, records,
equipment, supplies and other sources.
Dated: July 12, 2007.
Joe W. Ellis,
Assistant Secretary for Administration and
Management.
[FR Doc. 07–3547 Filed 7–20–07; 8:45 am]
BILLING CODE 4150–04–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
James David Lieber, University of
California at Los Angeles: Based on the
findings of an inquiry report by the
University of California at Los Angeles
(UCLA) and additional analysis and
information obtained by the Office of
Research Integrity (ORI) during its
oversight review, the U.S. Public Health
Service (PHS) found that James David
Lieber, Staff Research Associate, Semel
Institute for Neuroscience and Human
Behavior, Integrated Substance Abuse
Programs, UCLA, engaged in research
misconduct in research funded by
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH), grant R01 DA15390.
Mr. Lieber knowingly and
intentionally falsified and fabricated
multiple follow-up interviews, urine
samples, and urine sample records of
human subject study participants and
entered such false and fabricated data
into the study’s data base. A total of 914
follow-up interviews of opiate users
were planned to be completed as part of
a study of gender differences in a follow
up of opiate users in California. Mr.
Lieber was assigned to interview 53 of
the 132 subjects located for the followup study. Over a six-month period, Mr.
Lieber falsely claimed to have
conducted face-to-face interviews for
the study while subsequent contacts
with the subjects revealed that they had
not been interviewed for the study. A
review by the institution determined
that the respondent fabricated
interviews for 20 of the 53 interviews
assigned to him. In addition, he falsified
the urine specimens for those 20
subjects and caused the entry of false
information into the study tracking and
locating data base for 11 subjects.
sroberts on PROD1PC70 with NOTICES
SUMMARY:
VerDate Aug<31>2005
17:09 Jul 20, 2007
Jkt 211001
Aggravating factors included the theft of
$5180 for incentive payments to
subjects and travel expenses.
ORI has implemented the following
administrative actions for a period of
three (3) years, beginning on July 2,
2007:
(1) Mr. Lieber is debarred from
eligibility for any contracting or
subcontracting with any agency of the
United States Government and from
eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ as defined in
HHS’ implementation of OMB
Guidelines to Agencies on
Governmentwide Debarment and
Suspension at 2 CFR part 376, et seq.;
and
(2) Mr. Lieber is prohibited from
serving in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E7–14185 Filed 7–20–07; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Secondary
Review Panel for Translation
Research; Improving Public Health
Practice through Translation Research
(R18), Request for Application (RFA)
CD07–005
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Time and Date: 1 p.m.–3 p.m., August 7,
2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of programmatic relevance and
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
40157
priority of grant applications received in
response to RFA CD07–005, ‘‘Improving
Public Health Practice through Translation
Research (R18).’’
FOR FURTHER INFORMATION CONTACT:
Juliana Cyril, PhD, Scientific Program
Administrator, Office of Extramural
Research, CDC, 1600 Clifton Road NE.,
Mailstop D72, Atlanta, GA 30333,
Telephone 404.639.4639.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Edward Schultz,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–14148 Filed 7–20–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999D–2013 (formerly Docket
No. 99D–2013)]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Draft Guidance for
Industry: Cooperative Manufacturing
Arrangements for Licensed Biologics
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the proposed collection of information
concerning cooperative manufacturing
arrangements for licensed biologics.
DATES: Submit written or electronic
comments on the collection of
information by September 21, 2007.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
E:\FR\FM\23JYN1.SGM
23JYN1
]]>Agencies
[Federal Register Volume 72, Number 140 (Monday, July 23, 2007)]
[Notices]
[Page 40157]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-14185]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
James David Lieber, University of California at Los Angeles: Based
on the findings of an inquiry report by the University of California at
Los Angeles (UCLA) and additional analysis and information obtained by
the Office of Research Integrity (ORI) during its oversight review, the
U.S. Public Health Service (PHS) found that James David Lieber, Staff
Research Associate, Semel Institute for Neuroscience and Human
Behavior, Integrated Substance Abuse Programs, UCLA, engaged in
research misconduct in research funded by National Institute on Drug
Abuse (NIDA), National Institutes of Health (NIH), grant R01 DA15390.
Mr. Lieber knowingly and intentionally falsified and fabricated
multiple follow-up interviews, urine samples, and urine sample records
of human subject study participants and entered such false and
fabricated data into the study's data base. A total of 914 follow-up
interviews of opiate users were planned to be completed as part of a
study of gender differences in a follow up of opiate users in
California. Mr. Lieber was assigned to interview 53 of the 132 subjects
located for the follow-up study. Over a six-month period, Mr. Lieber
falsely claimed to have conducted face-to-face interviews for the study
while subsequent contacts with the subjects revealed that they had not
been interviewed for the study. A review by the institution determined
that the respondent fabricated interviews for 20 of the 53 interviews
assigned to him. In addition, he falsified the urine specimens for
those 20 subjects and caused the entry of false information into the
study tracking and locating data base for 11 subjects. Aggravating
factors included the theft of $5180 for incentive payments to subjects
and travel expenses.
ORI has implemented the following administrative actions for a
period of three (3) years, beginning on July 2, 2007:
(1) Mr. Lieber is debarred from eligibility for any contracting or
subcontracting with any agency of the United States Government and from
eligibility or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' as defined in
HHS' implementation of OMB Guidelines to Agencies on Governmentwide
Debarment and Suspension at 2 CFR part 376, et seq.; and
(2) Mr. Lieber is prohibited from serving in any advisory capacity
to PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E7-14185 Filed 7-20-07; 8:45 am]
BILLING CODE 4150-31-P
